Navigation Links
Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
Date:9/25/2008

potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

About ARCA biopharma

ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that predict individual patient response to Gencaro. The companion genetic test for Gencaro is in development by ARCA's partner, Laboratory Corporation of America. For more information please visit http://www.arcabiopharma.com.

Forward-looking statements

This press release contains "forward-looking statements" which include, without limitation, statements regarding the completion of the proposed merger transaction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc., the transaction's anticipated benefits, timing, progress and anticipated completion of the combined company's clinical stage and research programs, including possible regulatory approval, the potential benefits that patients may experience from the use of the combined company's clinical stage compounds, and the cash position of the combined company, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securitie
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
5. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
6. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
7. China Biopharma Effects 1 for 100 Reverse Stock Split
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. Therapure Biopharma Inc. opens for business with first client contracts
10. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... of Outstanding Issues (LOI) from the European Medicines Agency,s ... the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained ... candidate being evaluated for weight loss. The ... were adequately addressed by the Company based in part ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... Immunology Summit-2014 will ... Investigators, scientists in the field, which includes prominent ... Case Western Reserve University School of Medicine, USA, ... “The effects of recombinant human IL-6 and ... Arya Biragyn, a Senior investigator at National Institute ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... diaphragms-- women have many options for planning their fertility, none ... to help out? They have only two options -- vasectomy, ... dating but get old in long-term relationships. Will men ... is every calling them "Daddy" before they are ready? , ...
... ... 31, 2007, MILWAUKEE, Sept. 28 The American Academy ... in the United States representing allergists, asthma,specialists, clinical immunologists, allied ... and treatment of allergic disease,is now accepting entries for the ...
... QC, Sept. 28 /PRNewswire-FirstCall/ - Neptune Technologies &,Bioressources ... its,financial results for the fiscal year ended May ... its productivity and operational,profitability while continuing its business ... markets, resulting in,sustainable sales growth. Financial Results ...
Cached Biology Technology:Of mice and men: new male contraceptives successful in rodents and humans 2AAAAI: Call for Entries: Have You Written a Story on Allergic Disease? Win $1000 2Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results 2Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results 3
(Date:7/30/2014)... 2014 NexID Biometrics , a ... solutions for the biometric authentication industry, has recently ... online authentication with standards for strong authentication. According ... decision to join FIDO Alliance stems from NexID,s ... use. We believe the FIDO Alliance is a ...
(Date:7/30/2014)... Long before humans figured out how to create colors, ... bright butterfly wings of many different hues, for example. ... a more environmentally friendly way to make colored plastics. ... and architectures of materials rather than dyes, to ... Letters . , N. Asger Mortensen, Anders Kristensen and ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2F1000Research brings static research figures to life 2
... Borlaug and Rob Horsch of the Gates Foundation will discuss ... to kick off the International Annual Meetings of the American ... and Soil Science Society of America (SSSA) in New Orleans. ... 8 pm in the Grand Ballroom of the Hilton Riverside. ...
... a source of carbon dioxide to the atmosphere, according to ... The study was carried out by an international team of ... Belgium, and the University of Exeter in the U.K. ... other greenhouse gases, trap heat in the Earth,s atmosphere and ...
... State University was awarded a three-year grant from ... social, cultural and economic impacts of the "biofuels ... The $696,827 grant comes from the department,s Ethical, ... Bioenergy Technologies, Synthetic Genomes or Nanotechnologies program. The ...
Cached Biology News:Norman Borlaug, Rob Horsch to keynote world hunger lecture 2Agricultural soil erosion is not adding to global warming 2K-State sociologists use Department of Energy grant 2
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... demand is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... work and endeavour! Bring us your idea and ... internationally. We work under ISO 9001 quality assurance ...
... demand is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... work and endeavour! Bring us your idea and ... internationally. We work under ISO 9001 quality assurance ...
Topoisomerase I...
Biology Products: